Literature DB >> 16235992

Genetic polymorphisms of CYP2E1 and GSTP1 in a South Indian population--comparison with North Indians, Caucasians and Chinese.

S S Soya1, N Padmaja, C Adithan.   

Abstract

CYP2E1 and GSTP1 enzymes belong to phase I and phase II group of drug metabolizing enzymes respectively which are involved in the metabolic activation and detoxification of various potential genotoxic compounds. The functional polymorphism in these genes exhibit inter-individual variations in susceptibility towards various diseases and difference in therapeutic response. The variant sequences of these genes differ considerably between ethnic groups. Therefore, the objective of the study was to assess the prevalence of CYP2E1 & GSTP1 gene variants in healthy volunteers of Tamilnadu, a population of South India. The genotype distribution of CYP2E1*1B A2A2, A2A1 and A1A1 were 61%, 36% and 3% respectively. The distribution of CYP2E1*5B c1c1, c1c2 genotypes were 99.2%and 0.8%. CYP2E1*6 DD, DC and CC genotype frequencies were 72%, 25% and 3% respectively. The allele frequencies of CYP2E1*1B, CYP2E1*5B and CYP2E1*6 were A2- 0.79 A1- 0.21, c1-0.996 c2 - 0.004 and D- 0.84 C- 0.16 respectively. The genotypic distribution of GSTP1 (Ile/Val) were Ile/Ile - 44%, Ile/Val -47% and Val/Val- 9 % whereas, the allelic frequencies were 0.67 for Ile and 0.33 for Val allele. The molecular studies in these enzymes provide basis for further epidemiological investigations in the population where the functional mutations in the genes alter therapeutic response and acts as susceptibility markers for various clinical conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16235992

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  8 in total

1.  Role of CYP2E1 gene polymorphisms association with hepatitis risk in Northeast India.

Authors:  Manab Deka; Moumita Bose; Bharati Baruah; Purabi Deka Bose; Subhash Medhi; Sujoy Bose; Anjan Saikia; Premashish Kar
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

Review 2.  Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.

Authors:  Gurusamy Umamaheswaran; Dhakchinamoorthi Krishna Kumar; Chandrasekaran Adithan
Journal:  Indian J Med Res       Date:  2014-01       Impact factor: 2.375

3.  Genetic polymorphism of glutathione S-transferase P1 (GSTP1) in Delhi population and comparison with other global populations.

Authors:  Anita Sharma; Arvind Pandey; Shashi Sharma; Indranil Chatterjee; Ravi Mehrotra; Ashok Sehgal; Joginder K Sharma
Journal:  Meta Gene       Date:  2014-01-20

4.  The Interaction between GSTT1, GSTM1, and GSTP1 Ile105Val Gene Polymorphisms and Environmental Risk Factors in Premalignant Gastric Lesions Risk.

Authors:  Anca Negovan; Mihaela Iancu; Valeriu Moldovan; Simona Mocan; Claudia Banescu
Journal:  Biomed Res Int       Date:  2017-01-15       Impact factor: 3.411

5.  The genetic profiles of CYP1A1, CYP1A2 and CYP2E1 enzymes as susceptibility factor in xenobiotic toxicity in Turkish population.

Authors:  Merve Arici; Gül Özhan
Journal:  Saudi Pharm J       Date:  2016-06-16       Impact factor: 4.330

6.  Polymorphisms of drug-metabolizing enzyme CYP2E1 in Chinese Uygur population.

Authors:  Linhao Zhu; Yongjun He; Fanglin Niu; Mengdan Yan; Jing Li; Dongya Yuan; Tianbo Jin
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.817

7.  Genetic polymorphism of the drug-metabolizing enzyme Cytochrome P4502E1 (CYP2E1) in a healthy Saudi population.

Authors:  Lenah S Binmahfouz; Amina M Bagher
Journal:  Saudi Pharm J       Date:  2021-10-06       Impact factor: 4.330

8.  Evaluation of cytochrome P4502E1 polymorphisms in healthy adult Western Indians and patients with antituberculous drug-induced hepatotoxicity.

Authors:  Nithya J Gogtay; Swapnali R Kapileshwar; Sanket U Shah; Shital R Bendkhale; Suresh Ramakrishna; Kannan Sridharan; B K Thelma; Urmila M Thatte; Nilima A Kshirsagar
Journal:  Indian J Pharmacol       Date:  2016 Jan-Feb       Impact factor: 1.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.